Kidney Cancer Patients Unlikely To Respond To Potential Treatment Drug

... Mayo Clinic Cancer Center investigators report that imatinib mesylate (GleevecTM), the drug used to treat patients with gastrointestinal stromal cancers (GISTs), is not likely to be effective for patients with high grade renal cell carcinoma - the most aggressive kidney cancer. Results of the study are published in the January issue of The Journal of Urology... click link for more info. ...